임상 레이더 AI | ||
|---|---|---|
임상시험 NCT02734667은(는) 제1형 당뇨병에 대해 완료 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요. | ||
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes 120
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '임상시험 설명'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT02734667은(는) 제1형 당뇨병에 대해 알아본 중재연구입니다. 현재 상태는 완료입니다. 연구는 2016년 2월 1일에 시작되어 120명의 참여자와 함께 진행되었습니다. Korey Hood이(가) 진행한 이 연구는 2020년 2월 1일에 마무리되었습니다. ClinicalTrials.gov의 가장 최근 정보는 2022년 3월 2일에 갱신되었습니다.
간단한 개요
The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D). The investigators hope to learn about how continuous glucose monitoring affects glycemic variables and diabetes-related distress.
상세한 설명
Synopsis of study protocol
This pilot randomized clinical trial compares newly diagnosed T1D youth who are started on CGM (the intervention group) versus those who are not (the control group). The investigators will examine group differences over a 6-month period (Phase 1) on two sets of outcomes: psychosocial variables and glycemic variables. After the initial comparison of intervention to control across the first ...
더 보기공식 제목
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
질환명
제1형 당뇨병기타 연구 식별자
- 35990
NCT 번호
실제 연구 시작일
2016-02
최신 업데이트 게시
2022-03-02
예상 연구 완료일
2020-02
계획된 등록 인원
120
연구종류
중재연구
단계/상
해당 없음
상태
완료
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
없음 (오픈 라벨)
시험군 / 개입
| 참가자 그룹/시험군 | 개입/치료 |
|---|---|
실험적CGM at diagnosis of T1D Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months. | CGM at diagnosis of T1D Initiation of non-adjunctive CGM use at diagnosis of T1D |
비개입Usual Care Participants receive usual care for T1D for 6 months post diagnosis. | 해당 없음 |
주요결과변수
이차결과변수
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Time Spent in Blood Glucose Range (70-180mg/dL) | Increasingly it is recognized that the percent time spent in a target blood glucose range, which is set by the American Diabetes Association, is an important outcome. This measure will be used as a primary outcome and derived from objective data downloads. It is calculated using the values for 14 days around the assessment time point. | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
Glucose Monitoring Satisfaction Survey (GMSS) - Parent | The GMSS is a validated survey created to measure the level of satisfaction a person with diabetes - type 1 or type 2 - experiences in response to monitoring glucose values. It was validated in people using CGM. Scores range 0 to 5 with higher scores indicating greater satisfaction. | Baseline, 24 months |
Time Spent in Hypoglycemia (< 70 mg/dL) | Time spent in hypoglycemia is calculated using the values for 14 days around the assessment time point. | Collected entire period for 6 months post-baseline; primary endpoint is 14 day period around that 6-month time point |
| 결과변수 | 측정값 설명 | 시간 범위 |
|---|---|---|
Pediatric Quality of Life Inventory | This is a measure of health-related quality of life. It is used to understand the broader impact on quality of life which includes social, psychological, and health aspects of daily living. Scores range from 0 to 100. Higher scores indicate greater quality of life. | Baseline, 24 months |
Problem Areas in Diabetes Score | Participants in the study report on daily problems with diabetes via this measure. Respondents indicate the degree to which each of the items is currently a problem for them. Score range: 0 to 4, higher scores correspond to more serious problems. | Baseline, 24 months |
Diabetes Distress Scale | This measure is widely used to capture the psychological distress experienced in relation to diabetes. Parent scale score range: 0-4. Youth scale score range: 1-6. Higher scores indicate greater diabetes-related distress. | Baseline, 24 months |
Patient Health Questionnaire 9 | This is a widely used measure that captures depressive symptoms, and was used to assess health symptoms in parents. Score range: 0-24. Higher scores indicate greater severity of symptoms. | Baseline, 24 months |
State-Trait Anxiety Inventory | This is a widely used measure of anxiety symptoms, and was used to assess anxiety symptoms in parents. Score range for both state-anxiety is: 20-80. Higher scores indicate greater anxiety. | Baseline, 24 months |
Pittsburgh Sleep Quality Index | This questionnaire measures the degree to which sleep is disrupted and the quality of sleep experienced by participants, and was used to assess sleep quality in parents. Score range is: 0-21. Higher scores indicate lower sleep quality. | Baseline, 24 months |
Hypoglycemic Fear Survey | People with diabetes worry about hypoglycemia, and was used to assess parent's worry about their child. This measure captures those worries. Score range: 0-72. Higher scores indicate greater fear and worry of hypoglycemia. | Baseline, 24 months |
Hypoglycemic Confidence Questionnaire | Hypoglycemia needs to be managed in various daily situations. This questionnaire captures confidence of the participants in those various situations, and was used to assess parent's confidence. Score range: 8-32. Higher scores indicate greater confidence to manage hypoglycemia. | Baseline, 24 months |
General and Diabetes-specific Technology Use | This measure has questions on attitudes and use of various general technologies (e.g., smartphone) and diabetes devices. Score range: 5-25. Higher scores indicate more positive attitudes about technology. | Baseline, 24 months |
Center for Epidemiologic Studies Depression Measure | This is a widely used measure of depression, and was used to assess depression symptoms in youths. Score range: 0-60. Higher scores indicate greater symptoms. | Baseline, 24 months |
Child Health Utility 9D | Widely used measure of quality of life that is used to generate quality-adjusted life years, and was used to assess health symptoms in youth. Each score scale is 0 to 4, with scores of 3 or 4 denoting more severe problems. The count of participants responding 3 or higher for each parameter are presented. | Baseline, 24 months |
Hemoglobin A1c | The hemoglobin A1c value is a biologic measure of the glycemia that is the gold standard measure of "control" of diabetes. Collected through a blood sample. | Baseline, 24 months |
C-peptide | This is a biologic measure of endogenous production and is collected through a blood sample. | Baseline, 24 months |
적격성 기준
연령대
어린이
최소 연령
2 Years
참여 가능한 성별
전체
To be eligible for the study, a child must meet the following criteria:
- Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria
- Time since diagnosis of no longer than one month
- Age between 2 and 17 years
- Parental consent (and assent from the child where applicable) to participate in the study
- No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.
To be eligible for the study, a parent must meet the following criteria:
- Parent or legal guardian of a child with type 1 diabetes meeting the "child" criteria outlined above
- Age of 18.0 years or older
- Parent comprehends written English
- Parent understands the study protocol and signs the informed consent document
The presence of any of the following is an exclusion for the study:
- Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).
- Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol
- Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study
- Child is unable to completely avoid acetaminophen for duration of study
Korey Hood콜로라도 대학교 덴버480개의 진행 중인 임상시험 탐색 가능연구 책임자
Korey Hood, 의뢰자-연구자, Clinical Professor, Stanford University
연락처 정보가 없습니다.
2 1개국에 임상시험 장소
California
Stanford University, Stanford, California, 94305, United States
Colorado
University of Colorado, Aurora, Colorado, 80045, United States